For best results when printing this announcement, please click on the link below:
Actelion Pharmaceuticals Ltd / Actelion to present at the 31st Annual J.P. Morgan Healthcare
Conference - Delivering on our strategy . Processed and transmitted by Thomson Reuters ONE. The
issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 07 January 2013- Actelion Ltd (SIX: ATLN) Actelion Ltd (SIX: ATLN)
announced today that Jean-Paul Clozel, M.D., Chief Executive Officer of Actelion, will present at
the J. P. Morgan Healthcare Conference on Tuesday, 08 January 2013 at 9.30 a.m. Pacific time /
18.30 hrs Swiss time at the Westin St. Francis Hotel in San Francisco, CA.
Dr. Clozel will describe the progress made during 2012 in delivering on the three elements of
Actelion's strategy for value creation.
1) Sustain and grow the PAH franchise
Dr. Clozel will present an overview of Actelion's current product offerings in the pulmonary
arterial hypertension (PAH) market. He will also describe the excellent morbidity / mortality
outcome data from the SERAPHIN study with macitentan (Opsumit(R)). This novel and differentiated
dual endothelin receptor antagonist (ERA) was the result of a tailored drug discovery process in
In addition, Dr. Clozel will describe the opportunity for the Company's selective IP receptor
agonist, selexipag - developed together with Nippon Shinyaku - which has now enrolled over 1,000
patients into GRIPHON, a pivotal study also designed to demonstrate a reduction in the risk of
Dr. Clozel will present how Actelion's franchise today and in the future has the potential to
reshape the treatment paradigm in PAH.
2) Build an additional specialty franchise
Dr. Clozel will also present the positive results with the Company's innovative compounds,
ponesimod in psoriasis and cadazolid in Clostridium difficile associated diarrhea. At the end of
2012, mid-stage clinical studies reported results that allowed Actelion to decide to pursue both
compounds in Phase III development. This provides Actelion with the foundation for its mid-term
goal of building an additional specialty franchise.
3) Optimize profitability
As the third element to Actelion's strategy, the company is committed to profit growth in the
coming years and to value creation for shareholders. Dr. Clozel will present the measures taken to
ensure the company can deliver on these commitments and the company's near and mid-term core
Jean-Paul Clozel, MD and Chief Executive Officer of Actelion commented: "At last year's J. P.
Morgan conference I told the audience that 2012 would be an important year for Actelion. I am very
pleased to take this opportunity to describe the excellent progress the company has made to
deliver on our strategy for value creation. In 2013, and the years to come, Actelion will realize
the value it has created from innovation in our labs."
The presentation is available in pdf-format on www.actelion.com http://www.actelion.com/ . To
access the live and subsequently archived webcast of the presentation, visit "Events" in the
Investor Relations section of Actelion's corporate website. An archived replay will be available
for 3 months beginning 24 hours after the live presentation.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel,
Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor
antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets
Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States
(based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland.
Actelion, founded in late 1997, is a leading player in innovative science related to the
endothelium - the single layer of cells separating every blood vessel from the blood stream.
Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative
drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange
(ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI(R)).
For further information please contact:
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
The above information contains certain "forward-looking statements", relating to the company's
business, which can be identified by the use of forward-looking terminology such as "estimates",
"believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be",
"seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans
or intentions. Such statements include descriptions of the company's investment and research and
development programs and anticipated expenditures in connection therewith, descriptions of new
products expected to be introduced by the company and anticipated customer demand for such
products and products in the company's existing portfolio. Such statements reflect the current
views of the company with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or achievements of the
company to be materially different from any future results, performances or achievements that may
be expressed or implied by such forward-looking statements. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect, actual results may
vary materially from those described herein as anticipated, believed, estimated or expected.
Press Release PDF http://hugin.info/131801/R/1668485/541764.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland